BioPharma Resources

Drug Trial Radar · NCT01117441

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia

Last checked: Nov 19, 2026Latest source record: May 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 6,136 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,136

Actual

Start

Jun 2010

Primary completion

Dec 31, 2021

Study completion Dec 31, 2021

Sponsor

Lead sponsor
University Hospital Schleswig-HolsteinAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Deutsche Krebshilfe e.V., Bonn (Germany)
First posted
May 5, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 1 year, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Rationale/Purpose: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating young patients with acute lymphoblastic leukemia (ALL). This trial is studying several different combination chemotherapy regimens to compare how well they work in treating young patients with ALL. Study objectives Primary study questions: * Non high-risk (non-HR) precursor-B ALL (pB-ALL) patients with TEL/AML1-negative ALL or unknown TEL/AML1 status and flow cytometry minimal residual disease (MRD) in bone marrow on day 15 \<0.1% or with TEL/AML1-positive ALL (randomized study question R1): Can the daunorubicin dose in Protocol IA be safely reduced by 50 % with a non-inferior EFS and a reduction of toxicity (treatment-related mortality and AE/SAE in Protocol I)? * Patients with pB-ALL and risk group medium risk (MR) (randomized study question R2): Can the clinical outcome be improved by protracted asparagine depletion achieved through application of intensified PEG-L-asparaginase during reintensification and early maintenance? * High-risk (HR) patients (as identified by day 33 - randomized study question RHR): Can the clinical outcome be improved by protracted exposure to PEG-L-asparaginase during Protocol IB? Secondary study questions: * Standard risk (SR) patients identified by at least one sensitive marker: Is the clinical outcome comparable to that obtained in SR patients (identified with two sensitive markers) in AIEOP-BFM ALL 2000, or can the outcome even be improved with the use of PEG-L-asparaginase instead of native E. coli L-ASP? * T-ALL non-HR patients: Can the high level of outcome which was obtained for these patients in study AIEOP-BFM ALL 2000 be preserved or even improved with the use of PEG-L-ASP instead of native E. coli L-ASP? * HR patients with persisting high MRD levels despite the use of the HR blocks in the intensified consolidation phase "MRD Non-Responders": Is it possible to improve the outcome and to achieve a further reduction of leukemic cell burden by administration of an innovative treatment schedule (DNX-FLA)? * Patients participating in the randomized asparaginase studies (pB-ALL/MR, HR): Are asparaginase activity and asparaginase antibodies associated with development of allergic reactions, and do they have an effect on the outcome of the patients? * What is the relative value of different methods of MRD monitoring in the definition of alternative stratification systems within a BFM-oriented protocol?

Conditions

  • Leukemia

Interventions

  • PEG-L-asparaginaseDrug

    see detailed protocol description

  • cyclophosphamideDrug

    see detailed protocol description

  • cytarabineDrug

    see detailed protocol description

  • daunorubicin hydrochlorideDrug

    see detailed protocol description

  • dexamethasoneDrug

    see detailed protocol description

  • doxorubicin hydrochlorideDrug

    see detailed protocol description

  • etoposideDrug

    see detailed protocol description

  • ifosfamideDrug

    see detailed protocol description

  • mercaptopurineDrug

    see detailed protocol description

  • methotrexateDrug

    see detailed protocol description

  • prednisoneDrug

    see detailed protocol description

  • thioguanineDrug

    see detailed protocol description

  • vincristine sulfateDrug

    see detailed protocol description

  • vindesineDrug

    see detailed protocol description

  • daunoxomeDrug

    see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment

  • fludarabineDrug

    see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment

  • Radiation TherapyRadiation

    for eligibility for radiotherapy see detailed protocol description

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survivalTime frame: 10 years from the start of recruitment
  2. Disease-free survivalTime frame: 10 years from the start of recruitment
  3. minimal residual disease (MRD)Time frame: week 12 of treatment

Locations

139 sites in 7 countries. Site status is shown where the registry gives one.

  • The Sydney Children's Hospital, Centre for Children's Cancer and Blood Disorders

    Randwick, Australia

  • The Children's Hospital at Westmead, Department of Oncology

    Westmead, Australia

  • Krankenhaus Dornbirn, Abt. für Kinder- und Jugendheilkunde

    Dornbirn, Austria

  • Univ.-Kinderklinik Graz, Abt. Pädiatrische Hämato-Onkologie

    Graz, Austria

  • Department f. Kinder- u. Jugendheilkunde, Universitätsklinik f. Pädiatrie II

    Innsbruck, Austria

  • A.oe. Landeskrankenhaus Klagenfurt, Abt. für Kinder- und Jugendheilkunde

    Klagenfurt, Austria

  • A.oe. Landeskrankenhaus Leoben, Abt. für Kinder und Jugendliche

    Leoben, Austria

  • Landes-Kinderklinik Linz, Haematologie/Onkologie

    Linz, Austria

  • St. Johanns Spital / Landeskrankenhaus, Salzburg, Kinderspital Abt. Kinder u. Jugendheilkunde

    Salzburg, Austria

  • St. Anna Kinderspital, Zentrum für Kinder- und Jugendheilkunde

    Vienna, Austria

  • University Hospital Brno, Department of Pediatric Oncology

    Brno, Czechia

  • Regional Hospital České Budějovice, Department of Pediatrics

    České Budějovice, Czechia

  • University Hospital Hradec Králové, Department of Pediatrics

    Hradec Králové, Czechia

  • University Hospital Olomouc, Department of Pediatrics

    Olomouc, Czechia

  • Teaching Hospital Ostrava-Poruba, Department of Pediatrics

    Ostrava-Poruba, Czechia

  • University Hospital Plzeň, Department of Pediatrics

    Pilsen, Czechia

  • University Hospital Motol, Department of Pediatric Hematology and Oncology

    Prague, Czechia

  • Masaryk´s Hospital Ústí nad Labem, Department of Pediatrics

    Ústí nad Labem, Czechia

  • Kinderklinik der med. Fakultät der RWTH, Bereich Hämatologie/Onkologie

    Aachen, Germany

  • I. Klinik für Kinder u. Jugendliche, Klinikum Augsburg, Hämatologie/ Onkologie

    Augsburg, Germany

  • Klinikum Bayreuth, Kinderklinik

    Bayreuth, Germany

  • Klinikum Berlin-Buch II. Kinderklinik, Bereich Onkologie/Allg. Pädiatrie

    Berlin, Germany

  • Kinderklinik der Charité, Campus Virchow Klinikum (CVK), Abt.: Kinderhämatologie

    Berlin, Germany

  • Städtisches Krankenhaus, Kinderklinik

    Braunschweig, Germany

  • Klinikum Chemnitz gGmbH, Klinik für Kinder- und Jugendmedizin, Hämatologie / Onkologie

    Chemnitz, Germany

  • Kliniken der Stadt Köln GmbH, Kinderkrankenhaus Riehl

    Cologne, Germany

  • Med. Einrichtungen der Universität zu Köln, Klinik für Allg. Kinderheilkunde, Onkologisch-hämatologische Station

    Cologne, Germany

  • Carl-Thiem-Klinikum, Kinderklinik, Abt. Hämatologie/Onkologie

    Cottbus, Germany

  • Vestische Kinder- u. Jugendklinik, Universitätsklinik Witten/Herdecke

    Datteln, Germany

  • Klinikum Lippe-Detmold, Kinder- und Jugendmedizin

    Detmold, Germany

  • Klinikum Dortmund, Klinik f. Kinder- und Jugendmedizin

    Dortmund, Germany

  • Uni.Klinik Carl Gustav Carus, Klinik f. Kinderheilkunde

    Dresden, Germany

  • Universitätskinderklinik

    Düsseldorf, Germany

  • Helios Klinikum Erfurt GmbH, Klinik für Kinderheilkunde

    Erfurt, Germany

  • Universitätsklinikum Erlangen, Kinder- und Jugendmedizin, Abt. für Onkologie/ Hämatologie/Immunologie

    Erlangen, Germany

  • Universitätsklinikum Essen, Kinderklinik, Hämatologie/Onkologie

    Essen, Germany

  • Universitäts-Kinderklinik, Klinik für Kinderheilkunde III, Pädiatrische Hämatologie/Onkologie

    Frankfurt, Germany

  • Universitäts-Kinderklinik, Haematologie/ Onkologie

    Freiburg im Breisgau, Germany

  • Klinikum der Justus-Liebig-Universität, Zentrum für Kinderheilkunde, Abt. Hämatologie/Onkologie

    Giessen, Germany

  • Universitäts-Kinderklinik Päd. I, Hämatologie/Onkologie

    Göttingen, Germany

Showing 40 of 139 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.